Get the Stockscreener App
87.87
1.89%
-1.69
Pre-market:
83.07
-4.80
-5.46%
Guardant Health Inc stock is traded at $87.87, with a volume of 1.66M.
It is down -1.89% in the last 24 hours and up +3.43% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$89.56
Open:
$88.55
24h Volume:
1.66M
Relative Volume:
0.82
Market Cap:
$11.53B
Revenue:
$982.02M
Net Income/Loss:
$-416.28M
P/E Ratio:
-26.51
EPS:
-3.3148
Net Cash Flow:
$-233.07M
1W Performance:
+2.53%
1M Performance:
+3.43%
6M Performance:
+26.71%
1Y Performance:
+92.53%
1-Day Range:
$83.19
$89.25
1-Week Range:
$83.19
$95.18
52-Week Range:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
87.87 | 11.85B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health Inc. posts 38.6% negative EPS miss vs estimatesCommunity Volume Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Guardant Health (GH) director Mignone gains 264 shares through RSU vesting - Stock Titan
As April Marks National Cancer Prevention and Early Detection Month, FDA-Approved Blood Test for Colorectal Cancer Screening Makes It Easier to Screen in Nevada - Nevada Business Magazine
Price-Driven Insight from (GH) for Rule-Based Strategy - Stock Traders Daily
Quinn Emanuel May Face More Sanctions In Guardant Fight - Law360
Guardant Health director exercises 232 RSUs into shares | GH Insider Trading - Stock Titan
Biopsy Devices Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Guardant Health, Inc. (NASDAQ:GH) Sees Large Growth in Short Interest - MarketBeat
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Tariq Musa, Guardant Health director, sells $9840 in stock By Investing.com - Investing.com Australia
Tariq Musa, Guardant Health director, sells $9840 in stock - Investing.com
Guardant Health (GH) director sells 116 shares after RSU conversion - Stock Titan
Guardant Health (GH) CLO RSUs Vest with Shares Withheld for Tax Obligations - Stock Titan
9,840-share Form 144 sale by Guardant Health (NASDAQ: GH) - Stock Titan
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Piper Sandler reiterates Guardant Health stock rating on ctDNA data By Investing.com - Investing.com Canada
Guardant Health: As April marks National Cancer Prevention and Early Detection Month, FDA-approved blood test for colorectal cancer screening makes it easier to screen in Wisconsin - WisBusiness
Guardant Health, Inc. $GH Position Cut by Massachusetts Financial Services Co. MA - MarketBeat
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors - MSN
Sumitomo Mitsui Trust Group Inc. Sells 113,649 Shares of Guardant Health, Inc. $GH - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Eastern Progress
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $115 - Moomoo
Mizuho Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
TD Cowen cuts Guardant Health stock price target on valuation By Investing.com - Investing.com Canada
Guardant Health, Inc. $GH Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Guardant Health, Inc. (GH) Stock Report: Exploring A Potential 65% Upside - DirectorsTalk Interviews
Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10 - Benzinga
Oscar, Guardant, Redwire, Gap, AFLAC: Insider Moves Shock Wall Street - TipRanks
Guardant Health Surges to $510 Million in Trading Volume as Insiders and Institutional Investors Dispute Over $81 Share Price - Bitget
Guardant Health (NASDAQ:GH) Shares Down 7%Time to Sell? - MarketBeat
(GH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health Inc (GH) Stock Price Down 4.62% on Apr 9 - GuruFocus
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view - MSN
US Market Recap: Is now the right time to enter Guardant Health IncEarnings Miss & Community Consensus Stock Picks - baoquankhu1.vn
Multi-Cancer Early Detection Testing Market to Reach USD 7.52 - openPR.com
Aberdeen Group Trims Stake in Guardant Health - National Today
Aberdeen Group plc Sells 40,577 Shares of Guardant Health, Inc. $GH - MarketBeat
Aug Summary: Can Guardant Health Inc keep up with sector leaders2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
Insider Sell: Terilyn Monroe Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) chief people officer sells $355k in stock - Investing.com India
Guardant Health Insider Sells $355K in Shares - National Today
Guardant Health (GH) chief people officer sells $355k in stock By Investing.com - Investing.com South Africa
Guardant Health (GH) Chief People Officer sells 3,832 shares in open market - Stock Titan
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Guardant Health (GH) Positioned for Potential Upside, Says Citi - GuruFocus
Canaccord reiterates Guardant Health stock rating on cancer test growth - Investing.com
How does Guardant Health Inc compare to its peers2026 Biggest Moves & Risk Managed Investment Strategies - baoquankhu1.vn
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):